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Background: A cluster, randomized, control trial of three dry-season rounds of a mass testing and treatment
intervention (MTAT) using rapid diagnostic tests (RDTs) and artemether-lumefantrine (AL) was conducted in
four districts in Southern Province, Zambia.
Methods: Data were collected on the costs and logistics of the intervention and paired with effectiveness
estimated from a community randomized control trial for the purpose of conducting a provider perspective
cost-effectiveness analysis of MTAT vs no MTAT (Standard of Care).
Results: Dry-season MTAT in this setting did not reduce malaria transmission sufficiently to permit transition
to a case-investigation strategy to then pursue malaria elimination, however, the intervention did substantially
reduce malaria illness and was a highly cost-effective intervention for malaria burden reduction in this moderate
transmission area. The cost per RDT administered was estimated to be USD4.39 (range: USD1.62-13.96) while the cost
per AL treatment administered was estimated to be USD34.74 (range: USD3.87-3,835). The net cost per disability
adjusted life year averted (incremental cost-effectiveness ratio) was estimated to be USD804.
Conclusions: The intervention appears to be highly cost-effective relative to World Health Organization
thresholds for malaria burden reduction in Zambia as compared to no MTAT. However, it was estimated that
population-wide mass drug administration is likely to be more cost-effective for burden reduction and for
transmission reduction compared to MTAT.
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The scale-up of vector control for malaria in sub-Saharan
Africa has been extensive in the past decade [1]. In the
context of this scale-up, there have been calls for malaria
elimination and eradication, and increased recognition
that control and elimination strategies may need to focus
on the parasite reservoir in addition to reductions in
human vector contact [2, 3]. The Zambian Ministry of
Health (MoH) National Malaria Control Centre (NMCC),
in collaboration with partners, has set high targets for* Correspondence: jyukich@tulane.edu
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unless otherwise stated.malaria control intervention coverage and reductions in
malaria burden, as outlined in the National Malaria
Strategic Plan [4]. There is now empirical evidence of
progress in rolling out malaria interventions to affected
communities and their effectiveness in reducing the
malaria burden in Zambia [5–11]. The Malaria Indicator
Surveys conducted in 2006–2012 have shown substantial
progress in making malaria control services widely avail-
able in Zambia, including prompt effective case manage-
ment, possession and use of insecticide-treated mosquito
nets (ITNs), availability of indoor residual spraying (IRS),
and intermittent preventive treatment (IPTp) for preg-
nant women. Further, these surveys showed a reduction
of national malaria parasite prevalence and severe anaemial. This is an Open Access article distributed under the terms of the Creative
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these results suggest Zambia is moving towards measurable
health impact as a result of scaled malaria interventions,
they also suggest that even with high coverage of vector
control and diagnosis and treatment, additional steps are
necessary to continue to reduce the malaria burden among
those at risk.
For these reasons the NMCC decided to embark on a
large-scale trial, in the context of sustaining high vector
control coverage, of three dry-season rounds of a mass
testing and treatment intervention (MTAT) aimed at re-
ducing the parasite reservoir in humans in southern Zambia
as well as possibly interrupting transmission [12]. The
MTAT strategy used rapid diagnostic tests (RDTs) to iden-
tify individuals with parasite infections in the community
and treated those with a positive RDT with artemether-
lumefantrine (AL). While mass drug administration (MDA)
(the administration of an anti-malarial drug at therapeutic
doses to an entire population) is known to at least tempor-
arily reduce the burden of malaria in some settings, less is
known about the effectiveness of MTAT campaigns [13].
Dynamic, deterministic, mathematical, malaria modelling
indicates that it should increase the proportion of actual
infections that receive effective treatment and thereby
reduce the burden of clinical malaria as well as reduce
the parasite reservoir with the possibility of eventually
interrupting transmission [14]. In contrast, recent micro-
simulation models indicate that such an approach is un-
likely to succeed in interrupting transmission but may be
a cost-effective way to reduce the burden of malaria after
vector control scale-up has been achieved but where a
moderate burden remains [15]. Given the uncertainty
surrounding model inputs there is need to verify the
effectiveness of these strategies in robust field trials.
Furthermore, the modelled finding that MTAT is a poten-
tially cost-effective burden reduction strategy in moderate
burden locations hinges not only on the effectiveness
estimates but also on cost and logistic estimates [15].
Unfortunately, very little information on the logistics,
costs and operational constraints of MTAT strategies
in sub-Saharan Africa is available in the literature from
which to base either the parameterization of such cost
models or to assist those involved in malaria control and
elimination programmes to adequately plan for the finan-
cing and operation of these strategies. This paper pre-
sents the findings of an economic evaluation of three
dry-season rounds on an MTAT intervention conducted
in Southern Province, Zambia in 2012, which was con-
ducted alongside a large-scale trial of the intervention
[12]. This study compares the cost and cost-effectiveness
of MTAT to Standard of Care (no MTAT) in southern
Zambia, additionally it uses sensitivity analysis to ex-
plore programme modifications including mass drug
administration.Methods
Study sites
Southern Province was identified in 2010 as a study site
for the MTAT trial because of its moderate malaria trans-
mission and sustained high vector control coverage in the
area. Four districts (Siavonga, Gwembe, Sinazongwe, and
southeastern Kalomo) within Southern Province were
selected along Lake Kariba on the southern border of
Zambia and Zimbabwe (Fig. 1). The study population
was estimated to be just over 330,000 people living in
approximately 56,000 households in 2011.
The results of the 2006–2012 National Malaria Indica-
tor Surveys identified Southern Province as an emerging
region with lower malaria parasite prevalence among
children [5, 9, 10], although facility-based reporting also
suggests that much higher malaria transmission persists
in districts along Lake Kariba.
Study design
The trial utilized a cluster randomized design. Health fa-
cility catchment areas were randomly allocated to be in-
cluded in the 2012 dry-season MTAT intervention arm,
with control areas slotted to receive the MTAT interven-
tion in subsequent years rolled out in a stepwise fashion.
In 2012, 40 % of the health facility catchment areas in-
cluded in the trial received the three dry-season MTAT
rounds.
Intervention
MTAT interventions were planned from 2011–2013 and
were conducted during the dry or low malaria transmis-
sion season, which stretches from the month of May to
November. The three MTAT rounds in 2012 were con-
ducted in June-July, August-September and October-
November. During each round, community health worker
(CHW) teams, organized at the health facility catchment
area level swept through the neighbouring community in
a house-to-house fashion and tested every consenting
household member using a RDT.
The systematic MTAT campaigns targeted all house-
hold members for malaria testing using RDTs within
intervention catchment areas. Informed consent was ob-
tained from all adult household members or parents or
guardians of children. Each CHW was accompanied by
one data assistant to capture key information about the
household and its members, including questions on re-
cent fever and treatment history, mosquito net posses-
sion, use and geo-location data. In the event that any
household members with recent history of fever were
not present during the household visit, or if any house-
hold members tested positive for malaria, the CHW
scheduled a time to revisit the household to test these
individuals. All RDT-positive individuals were treated
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Fig. 1 Map of Southern Province districts, health facilities and their catchment areas included in training and testing campaigns and trial
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to implementing MTAT campaigns, standardized train-
ing for CHWs and data assistants were conducted at a
central venue within each district. The training reviewed
diagnostic and treatment policies, research and consent
processes as well as field practical rehearsals to evaluate
and refine skill levels of field staff and supervisors.
Cost collection and analysis
Data on intervention costs covered all of 2012. The in-
gredients approach was used for line item cost estima-
tion. This means that inputs were identified, quantified,
valued and classified into activity categories. Where this
approach was not possible, either because the information
was deemed too sensitive or was not available in adequate
detail, aggregated expenditures were used or costs were
estimated using WHO-CHOICE data on cost and project
level data on activities [16]. Costs were classified as either
capital or recurrent costs and as either traded or non-
traded goods [17, 18]. In the base analysis all costs were
treated as recurrent with rental costs being used to value
capital goods included. Costs were initially measured in
one of three currencies, Zambian Kwacha (ZMK), US dol-
lars (USD) or International Dollars (when the source of
cost information was WHO-CHOICE). As all costs were
collected during the year 2012 no inflation adjustments
were necessary. Costs collected in ZMK were converted
to USD using official exchange rates [19]. All othercosts were first converted to USD based on official yearly
average exchange rates for the period during which the
costs were incurred and for purchasing power parity for
International Dollar costs using the World Bank purchas-
ing power parity index [19, 20]. All costs are reported in
2012 USD. Both financial and economic costs were esti-
mated in order to calculate the value of donated inputs as
well as the actual financial implications of the interven-
tion. Financial costs represent purely monetary flows,
while economic costs represent the value (opportunity
cost) of all resources necessary to implement a given inter-
vention. However, in the case of this study no substantial
donated items were used and few capital goods were used
and as such the differences between financial and eco-
nomic costs were negligible and only economic costs are
presented here. The provider perspective was used; travel
or time costs to recipients of the intervention were not
included, nor were other household-level costs or cost
savings. Household-level cost-savings due to averted need
for malaria case management among intervention bene-
ficiaries may have occurred. Household costs for the
intervention were believed to be negligible given that the
intervention is provided at no charge directly at household
level and the drugs administered have very low risk of ser-
ious side effects that would require any medical interven-
tion. Cost savings due to reduced treatment at the health
facility were modelled based on existing literature on the
cost of treatment of uncomplicated malaria cases at health
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incremental, existing infrastructure and recurrent inputs
that would be present without the intervention, such as
capital costs of building health facilities or training CHWs
for general roles outside this campaign, were not included.
Logistics and output data
Data on levels of effort and outputs of the programme,
including quantification of resource inputs such as artemi-
sinin combination therapy (ACT) treatment courses, RDT
kits, vehicle days, supervision days, and other programme
inputs, were collected directly using programme records.
Information on outputs, including the number of persons
tested and the number of persons treated was collected
from direct reports from CHWs administering the interven-
tion. Coverage of the intervention was estimated using both
administrative (implementers reports) data and through the
individual-level data collected during the MTAT rounds,
and by the use of census data collected at individual level
during the intervention.
Costing scenarios and sensitivity analysis
The base case costing scenario relied on the following set
of assumptions: a discount rate of 3 % was applied to cap-
ital costs; wastage of RDT kits, ACT treatment courses
and other field work materials was assumed to be 10 %;
overhead for national (and international) supervision
amounted to 15 % of the total direct financial costs of the
programme. These are believed to be conservative as-
sumptions. The cost of ACT treatment courses and RDT
kits were based on the cost, insurance and freight (cif.)
price of the drug or diagnostic derived from project re-
cords and the WHO Global Price Reporting Mechanism
(WHO-GPRM) database [22]. Test positivity rates and
population coverage estimates were assumed to be identicalTable 1 Results of one-way sensitivity analysis and scenario analyses
Parameter Base value Sensitivity analysis value Results
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avertedto those actually reported in the trial monitoring data set.
In order to examine the role of these assumptions in the
ultimate cost estimates, all of these parameters were var-
ied in sensitivity analyses, the results of which are detailed
in Table 1. Additionally, probabilistic sensitivity analysis
was used to conduct to include uncertainty around effect
and cost estimates. Catchment area level cost data was
used to estimate the parameters of the distribution of cost
estimates and uncertainty around effect estimates was de-
rived from the trial results [12]. The parameters around
these estimates are detailed in Table 2.
Outcome indicators
Several indicators of outcomes were calculated. These
were: 1) cost per person targeted, calculated as the total
costs of the intervention divided by the total number of
persons targeted to receive the intervention; 2) cost per
test administered, calculated as the total costs of the
intervention divided by the total number of tests actually
administered; and, 3) cost per treatment administered,
calculated as the total costs of the intervention divided
by the number of treatments administered. All outcome
indicators were disaggregated to the district and health
facility catchment area levels in order to facilitate sub-
analysis of district level factors and health facility catch-
ment area level factors associated with the cost-outcome
relationship.
Impact indicators
Several impact indicators were calculated: 1) cost per
case averted calculated as the total costs of the interven-
tion divided by the estimated number of malaria cases
averted after exposure to three rounds of MTAT from
the results of a regression model used to estimate the ef-
fects of the intervention in an accompanying paper [12];/implications Justification
ect/All costs treated
rrent
Covers all likely discount rate
applications [45]
er test administered rises
SD 4.39 to 4.83
Highest value found in WHO GPRM
database for an adult dose
er test administered rises
SD 4.39 to 6.32
Highest cost found in WHO GPRM
database
er test administered falls
SD 4.39 to 3.65
Approximate daily capital cost of a
vehicle based on WHO-CHOICE data
er test administered falls
SD 4.39 to 3.60
Enumerators contribute substantially
to research component and may be
unnecessary for intervention only
er test administered falls
SD4.39 to 3.66
Ongoing NGO and international
supervision may not be required if
made a routine intervention
cost per case averted rises
SD73 to 145/Gross cost per case
falls from USD 73 to USD 36
Duration of effect uncertain in effect
analysis [12, 14, 15]
Table 2 Parameter inputs to probabilistic sensitivity analysis
Parameter Input parameter value or distribution Justification
Incidence Poisson (lambda = 19.2) [12]
Case fatality Rate 0.0045 [44]
Cost per person tested Log-normal (mean log = 1.61, sd log = 0.38) Derived from source data
DALYs per death 33 [16]
Effect size Gamma (shape = 38.65, rate = 46.01) [12]
DALYs per uncomplicated malaria case 0.02 [28]
Cost per case for management of uncomplicated case at a health facility USD 6.12 [21]
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of the intervention divided by the number of deaths
averted for the entire targeted population based on the
incident rate ratio estimated for exposure to the inter-
vention over three rounds in a Poisson regression model,
based on passive malaria data collection in the health
facilities in the trial in an accompanying paper and an
assumed case fatality rate and duration of effect (CFR)
[12, 23–25]; and, 3) cost per disability adjusted life year
(DALY) averted calculated based on the total cost of the
intervention and the estimated numbers of DALYs averted
for the entire population of the intervention area. DALYs
averted were calculated based on the total number of
malaria cases and deaths averted using Global Burden
of Disease disability weights and assuming that all deaths
were among under-five children and resulted in approxi-
mately 33 DALYs lost [26–28]. The study and reporting
was checked against the consolidated health economic
evaluation reporting standards (CHEERS) checklist for
reporting of economic evaluations [29].
Results
During the three dry-season rounds of the 2012 MTAT,
a total of 269,668 tests were administered to an estimated
population of 135,649 in 18 health facility catchment areas.
Based on the results of the RDTs used, 34,056 people were
treated for Plasmodium falciparum infections with AL,
corresponding to a test positivity rate (TPR) of 12.6 %.
Overall, average coverage of the estimated population
during each round according to administrative data was
66.2 %, while coverage estimated using census data was
88.3 %; detailed results on coverage, treatment and testing
by district and round are shown in Table 3. Of the 21 facil-
ities that were included in the initial round, three facilities
were discontinued during rounds two and three leaving
the total intervention areas at 18. These excluded facilities
were not included in the cost analysis.
Total costs of the MTAT were approximately 1.2 mil-
lion USD and did not vary meaningfully by round but
did by district (Table 4), reflecting the large variation in
included populations by district, as shown in Table 3.
When costs are broken down by activity category thelargest cost drivers were personnel and vehicles, with
training and RDTs second (Table 5 and Fig. 2).
The overall cost per test administered was USD4.39,
while the overall cost per treatment administered was
USD34.74 (Table 6). RDTs themselves were estimated to
cost USD0.47 per kit and ACT was estimated to cost
USD1 for a child and USD1.25 for an adult, based on pro-
ject record data. Costs per test administered varied from
USD3.45 to 5.94 when summarized by district and round;
the range was wider when summarized by catchment area
(USD1.62-13.96). Costs per treatment administered were
substantially higher, with an overall estimate of USD34.74.
Costs per treatment administered varied widely when
summarized by district and round (USD13.38-260.10) and
even more widely when summarized by catchment area
(USD3.87-3,835). Costs per treatment administered gener-
ally rose from round one through round three reflecting
the declining RDT positivity rates and the subsequent
need for treatment, while no clear pattern was apparent
by round in cost per test administered.
Cost savings due to averted malaria cases at the health
facility and the number of deaths and DALYs averted were
estimated among the entire treatment population using
the overall programme effectiveness estimates from the
impact evaluation. The base case scenario results for im-
pact and cost effectiveness are shown in Table 7. The three
MTAT rounds were estimated to have prevented over
16,000 malaria cases and more than 30 deaths, resulting in
a net gain of more than 1,300 DALYs in the year following
the intervention. This translates to a cost-effectiveness esti-
mate of USD894 per DALY averted. Given that Zambia’s
current GDP per capita is estimated at USD1,414, and util-
izing WHO-CHOICE guidelines on cost effectiveness
thresholds (less than GDP per capita per DALY is consid-
ered highly cost effective (less than three times GDP per
capita is considered cost effective); this indicates that the
MTAT intervention as implemented in Southern Province,
Zambia should be considered a highly cost-effective health
intervention [16].
Cost per test administered and cost per treatment ad-
ministered varied by catchment area and round. Costs
per test administered varied minimally and appeared to
Table 3 Outputs of the mass testing and treatment intervention by round and district
Dis Total
Pop




















Gw 57,495 45,605 10,912 79.3 % 82.5 % 23.9 % 37,837 5,031 65.8 % 85.1 % 13.3 % 37,552 4,110 65.3 % 83.8 % 10.9 % 120,994 20,053 70.1 % 83.8 % 16.6 %
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Sin 22,000 18,174 5,267 82.6 % 94.8 % 2.9 % 17,110 3,660 77.8 % 96.8 % 2.1 % 17,508 2,463 79.6 % 89.4 % 1.4 % 52,792 11,390 80.0 % 93.6 % 2.2 %
Tot 135,649 93,902 17,522 69.2 % 86.2 % 18.7 % 88,740 9,465 65.4 % 90.7 % 10.7 % 87,026 7,078 64.2 % 88.2 % 8.1 % 269,668 34,065 66.3 % 88.3 % 12.6 %











Table 4 Total costs of the mass testing and treatment campaigns
by district and round
District Round 1 Round 2 Round 3 Total
Gwembe $ 208,993.65 $ 193,657.50 $ 191,981.78 $ 594,632.93
Kalomo $ 35,571.77 $ 35,914.88 $ 35,970.67 $ 107,457.32
Siavonga $ 92,632.91 $ 92,241.21 $ 92,335.87 $ 279,209.99
Sinazongwe $ 70,447.44 $ 66,727.51 $ 65,112.41 $ 202,287.36
Total $ 407,645.76 $ 390,541.10 $ 385,400.73 $ 1,183,587.59
Silumbe et al. Malaria Journal  (2015) 14:211 Page 7 of 13be independent of test positivity rate, while cost per treat-
ment administered varied widely as previously mentioned,
with a clear decreasing relationship to test positivity rate
in the area during the round (Fig. 3). There appeared to
be a small inverse relationship between catchment area
size and the cost per person treated, although the overall
magnitude is small (Fig. 4).
In order to determine the effect of various assumptions
made in the analysis on the conclusions of the study, a sen-
sitivity analysis was conducted. Sensitivity analysis indicated
that the results were most sensitive to the costs of vehicles
and the use of NGO staff and supervision (Table 1). None
of the assumptions tested in one-way sensitivity analysis
or scenario analysis altered the conclusion that the MTAT
intervention was highly cost-effective as implemented in
Southern Province, Zambia.
Figure 5 illustrates the results of the probabilistic sen-
sitivity analysis of effect size and cost. The majority of
simulation results lies in the first quadrant of the cost-
effectiveness plane, indicating that the intervention is ex-
pected to provide additional benefits but also to require
additional expenditure (Fig. 5). Detailed analysis of the re-
sults indicates that 81 % of simulations resulted in add-
itional costs but with a cost to effect (CE) ratio, which fell
below the WHO threshold for a highly cost effective-
intervention. Eighty-seven per cent of simulations led to
the conclusion that the intervention was at least a cost-
effective intervention (WHO thresholds are illustrated by
the red and blue lines in Fig. 5). Only 11 % of the simula-
tions fell in quadrant II, indicating that the interventionTable 5 Total costs by activity category
Activity category Total cost Contribution
Training $ 144,136 12 %
Printing $ 23,959 2 %
Personnel $ 435,066 37 %
Vehicles $ 199,964 17 %
ACT $ 46,993 4 %
RDTs $ 139,260 12 %
Other consumables $ 39,828 3 %
Overhead $ 154,381 13 %
Total $ 1,029,207 100 %would be both less effective and more costly than the
alternative (in other words, MTAT was dominated by
Standard of Care). The results are additionally shown
in the form of a cost-effectiveness acceptability curve
in Fig. 6.
Discussion
This paper demonstrates MTAT interventions are likely
to be highly cost-effective interventions for malaria bur-
den reduction in moderate transmission areas in
Zambia, but did not reduce prevalence of infection or
malaria transmission significantly enough for these areas
to proceed towards malaria elimination. This finding is
in line with several modelling exercises, which suggest
that MTAT is likely to provide burden reduction benefits
in areas of moderate and high transmission and be rela-
tively cost-effective at doing so [14, 15]. While this finding
is important, significant and likely to be robust, it also
needs to be taken carefully in context. Although MTAT
appears highly cost effective for malaria burden reduction,
the estimates reported here are more than an order of
magnitude higher than those found for several other mal-
aria control interventions, including long-lasting insecti-
cidal nets (LLINs) (range: USD8.15-110 per DALY), IRS
(range: USD135-150 per DALY) and IPTp (range: USD-
329-139 per DALY) [30, 31]. As such the current findings
should not be interpreted as a call to scale-up MTAT
where other interventions are still neglected. One math-
ematical model suggests that at ITN coverage levels simi-
lar to those found in the districts where this study was
conducted (>60 %), scale-up of MTAT might be similar in
cost-effectiveness to further scale-up of ITNs [15]. Esti-
mates of MTAT cost-effectiveness in this study show that
MTAT would not be competitive with initial LLIN scale-
up; however, the marginal cost-effectiveness of MTAT ver-
sus further scale-up of vector control may warrant further
study.
While the study indicated the possibility that some
cost savings in case management might accrue due to
the implementation of MTAT, these savings appear to be
modest compared to the costs of implementing the
MTAT intervention. This is due to the fact that many
uncomplicated malaria cases do not present at health fa-
cilities, where cost savings accrue to providers, and also
to the relatively modest cost of treating an uncompli-
cated malaria case in the health system. This cost is very
modest, especially compared to the cost per treatment
administered in the very low test positivity rate areas in
the study [21], indicating that, unsurprisingly, MTAT
would be an extremely inefficient way to administer
treatments for symptomatic infections (given the low
prevalence of currently symptomatic infections in the
population) in low transmission areas. In very low trans-
mission areas, especially those with good health system
Fig. 2 Distribution of costs by district
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generally expected to be symptomatic it may not be an
efficient way to treat malaria infections. Even in loca-
tions where health system access is poor, investments in
the improvement in health care access, such as commu-
nity case management, may be more efficient at reaching
infected individuals, given the massive numbers of indi-
viduals who must be tested in order to identify an infection
for treatment under the MTAT intervention. Unfortunately
the costs of improving health system access in relevant
areas of Africa are not well understood and are understud-
ied. MTAT may offer the advantage of reaching individ-
uals in the general population who would never seek
medical care either because of limited access or be-
cause their infections have never become significantlyTable 6 Economic cost per output of the mass testing and treatme
and round
MTAT Round Gwembe
Cost per test administered Rd 1 $ 4.58
Rd 2 $ 5.12
Rd 3 $ 5.11
Total $ 4.91
Cost per treatment administered Rd 1 $ 19.15
Rd 2 $ 38.49
Rd 3 $ 46.71
Total $ 29.65symptomatic for them to do so. In elimination settings
MTAT might be useful even though it will require large
investment to identify a small number of infected individ-
uals. However, the effectiveness of MTAT to identify this
remaining infected reservoir is also limited by the sensitiv-
ity and specificity of the diagnostics used, the actual popu-
lation coverage achieved in the intervention, and the time
frame and geographic area over which such an extensive
investigation can be repeatedly conducted [13, 14, 32].
While this study can give no indication of the prob-
ability that interruption of transmission might occur due
to repeated MTAT in the study areas, it could provide
useful evidence on the cost of the use of MTAT as part
of a package of interventions targeted at elimination.
These data give some indication that there may bent (MTAT) campaigns in Southern Province, Zambia by district
Kalomo Siavonga Sinazongwe Total
$ 5.94 $ 3.84 $ 3.88 $ 4.34
$ 5.52 $ 3.45 $ 3.90 $ 4.40
$ 5.28 $ 3.67 $ 3.72 $ 4.43
$ 5.56 $ 3.65 $ 3.83 $ 4.39
$ 118.57 $ 88.81 $ 13.38 $ 23.26
$ 137.08 $ 184.06 $ 18.23 $ 41.26
$ 239.80 $ 260.10 $ 26.44 $ 54.45
$ 150.92 $ 146.18 $ 17.76 $ 34.74
Table 7 Outcome and impact indicators for the economic
evaluation of the mass testing and treatment campaigns
Outcome or impact Total Cost per outcome or impact
Tests administered 269,668 USD 4.39
Treatments administered 34,065 USD 34.74
Persons targeted 135,649 USD 8.73
Cases averted 16,278 Gross USD 72.71
Net USD 65.37
Estimated deaths averted 33 Gross USD 36,356
Net USD 32,686
DALYs averted 1,324 Gross USD 894
Net USD 804
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MTAT (see Fig. 4). However, these returns appear to be
modest at best.
MTAT is a variation of MDA, which has been made
possible by the development of rapid, inexpensive, point
of care diagnostics - malaria RDTs. However, given the
results here it is clear that MDA might be a more suit-
able approach to the treatment of prevalent malaria in-
fections. This is due to the fact that MDA removes the
cost of RDTs, and the time associated with the testing of
individuals prior to treatment. MDA is also likely to be
easier to administer at community treatment points than
MTAT. These two modifications could significantly reduceFig. 3 Cost per test and treatment administered versus prevalence. Red rep
treatment administeredthe costs and increase the drug coverage in the population.
MDA has been shown to significantly, temporarily reduce
malaria prevalence and incidence in many transmission
settings in the past [13]. A trial of MDA to replace MTAT
designed to measure these outcomes began in Southern
Province, Zambia in 2014.
Several objections to the approach proposed above
might be raised. These include: that shifting to commu-
nity treatment points could lead to declines in coverage,
that MDA may not be more effective than MTAT, espe-
cially if MTAT were implemented with a highly sensitive
and specific diagnostic, that adherence to treatment may
decline with the use of MDA as opposed to MTAT, and,
that the more wide-scale use of drugs implied by MDA
might create a more favourable environment for the de-
velopment or spread of drug resistance [33–35].
The coverage of the MTAT intervention was estimated
to be near 90 % using census data collected during the
intervention, however, administrative reports coupled with
health system denominators yielded much lower coverage
estimates. High coverage of MTAT is likely to be highly
important to successful implementation of the interven-
tion, especially where the goal of the intervention is local
elimination of the parasite reservoir. It is likely that
increased coverage would have led to improved outcomes
in this study and perhaps improved cost-effectiveness.
However, given that coverage of the intervention may
have been very high it is not likely that MTAT, at leastresents cost per test administered and green represents cost per
Fig. 4 Cost per treatment administered versus catchment population size
Fig. 5 Sensitivity analysis of effect size and cost variance. Hex-bins represent simulated cost and DALY averted outcomes, with lighter colour
indicating higher density of simulations, black lines are the x and y-axes of the chart. The green line is the WHO threshold for an intervention to
be considered highly cost-effective in Zambia (USD 1,414 per DALY averted) and the red line is the threshold at which an intervention is considered
cost-effective or not cost-effective in Zambia (3x GDP per capita) (USD 4,242 per DALY averted)
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Fig. 6 Probabilistic sensitivity analysis results shown as a cost-effectiveness acceptability curve. The vertical dotted lines represent the WHO
thresholds for an intervention to be considered highly cost-effective and cost-effective in Zambia: (USD 1,414 per DALY averted) and (USD 4,242
per DALY averted), respectively
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age and use of AL, to interrupt malaria transmission in
areas similar to Southern Province, Zambia.
Finally, little is known about treatment adherence with
MTAT interventions for malaria although reported cover-
age in MDA interventions has varied greatly [36–41].
However, the use of a therapy that requires the user to
take six doses over a period of three days is not ideal for
use in either MTAT or MDA. Failure to fully complete or
adhere to therapeutic recommendations for infectious dis-
eases has been shown in numerous settings, even among
symptomatic patients [42, 43]. Given both the relatively
limited access to health care in this setting and the rela-
tively limited access to resources of most of the population
there is a strong likelihood that a significant portion of pa-
tients will fail to complete therapy and instead reserve the
remainder of drug for a period in which they are ill.
The results of this study depend on a number of as-
sumptions; while the sensitivity analysis conducted herein
lends credence to the robustness of the results - especially
their internal validity - the risk remains that neither the
costs nor the effects may be generalizable. Because the
DALY burden for malaria is driven largely by mortality,
the assumed case fatality rate will have a large influence
on cost-effectiveness outcomes. The numbers are highly
uncertain and while this study uses WHO estimates, vari-
ation in this quantity could significantly alter results [44].
These results suggest that MTAT, while a highly cost-
effective intervention for malaria burden reduction, isstill a relatively expensive investment for malaria control
and is much less cost-effective than initial roll-out of
ITNs or IRS [30, 31]. Additionally, MTAT did not lead
to local elimination of malaria in any part of the study
area. There are, however, substantial benefits that are de-
rived from an intervention of this type, which cannot be
easily valued and included in such an analysis. Aside from
potential cost-savings due to averted treatments from the
household side, there are numerous benefits that were
not, or could not be, included. These include the improved
knowledge of household locations and parasite spatial
distribution which arise when conducting household-
to-household MTAT with attendant data collection and
household geo-location, and the reach of the health sys-
tem into communities with limited access to care.
In line with the goals of the National Malaria Strategic
Plan, optimal approaches aimed at further reducing mal-
aria infection in Zambia are needed given the existing
levels of malaria prevention coverage. Implementing an
MTAT campaign is a challenging and resource-intensive
activity requiring significant microplanning at every level
of the health system. This paper measures the costs of
implementing a campaign of house-to-house MTAT for
malaria. This study finds that MTAT is a highly cost-
effective intervention for burden reduction in moderate
transmission areas in Zambia and provides cost and lo-
gistic information which may be translatable to other
settings intending to implement an intervention of a
similar type.
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MTAT of entire populations for malaria infection is a
highly cost-effective intervention for malaria burden re-
duction in Southern Province, Zambia. However, the re-
ductions achieved were not sufficient for these areas to
transition into case investigation or to interrupt transmis-
sion. These finding are likely to be robust within areas of
moderate transmission and in other similar African set-
tings. However, MTAT remains a less efficient way to de-
liver drugs to a population (compared to MDA) although
it would likely result in lower drug pressure on the para-
site reservoir than would occur in a MDA campaign.
MTAT is less cost-effective than scale-up of the main
vector control interventions and should not be seen as an
alternative to scale-up of these proven vector control in-
terventions. In very low prevalence areas, MTAT may be
less efficient at delivering treatment than simple passive
health system treatment of active cases, although it likely
covers individuals who otherwise would not receive cura-
tive treatment.
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